# US 2014/0154290 A1 · Composition for prevention and treatment of allergic and/or inflammatory diseases > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0154290 A1 - Document ID: US20140154290A1 - Status: Published application - Kind: A1 - Application number: 14/059,180 - Filed: 2013-10-21 - Published: 2014-06-05 - Earliest claimed: 2008-08-16 - Assignees: Forschungszentrum Borstel; Protectimmun GmbH - Applicants: Forschungszentrum Borstel; Protectimmun GmbH - Inventors: Marcus Peters; Marion Kauth; Albrecht Bufe; Otto Holst - Web page: https://patentgrep.com/patent/US20140154290A1 ## CPC - A61K 38/168: {from plants} - A61K 31/715: Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters - A61K 35/10: Peat; Amber; Turf; Humus - A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00) - A61K 35/744: Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs - A61K 36/899: Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane - A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants - A61P 3/10: for hyperglycaemia, e.g. antidiabetics - A61P 5/50: for increasing or potentiating the activity of insulin - A61P 11/06: Antiasthmatics - A61P 17/00: Drugs for dermatological disorders - A61P 17/06: Antipsoriatics - A61P 19/02: for joint disorders, e.g. arthritis, arthrosis - A61P 25/00: Drugs for disorders of the nervous system - A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] - A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) - A61K 2039/55516: {Proteins; Peptides} - A61K 2039/55583: {Polysaccharides} - A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2} - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract A prophylactic antiallergenic composition includes at least one arabinogalactan or arabinogalactan protein. The arabinogalactan or arabinogalactan protein is isolated from a grass or corresponds in its structural arrangement to an arabinogalactan that can be isolated from a grass. ## Claims ### Claim 1 A method of reducing a likelihood of, protecting against or treating allergic diseases or chronic inflammatory diseases, comprising: administering a prophylactic antiallergenic composition comprising at least one arabinogalactan or arabinogalactan protein into a mammal that is in need of such reduction, protection or treatment, wherein said at least one arabinogalactan or arabinogalactan protein is isolated from at least one grass or corresponds in its structural arrangement to an arabinogalactan isolatable from at least one grass, wherein the allergic diseases or chronic inflammatory diseases are selected from the group consisting of IgE-dependent Type I allergic diseases or Type IV allergic diseases, chronic inflammatory skin diseases, and autoimmune diseases. ### Claim 2 (depends on 1) The method according to claim 1, wherein the allergic diseases are selected from the group consisting of IgE-dependent Type I allergic diseases. ### Claim 3 (depends on 1) The method according to claim 1, wherein the method is configured to reduce a likelihood of, protect against or treat one or more selected from the group consisting of hay fever, food allergy, asthma, urticaria, neurodermitis, atopic dermatitis, contact eczema, psoriasis, diabetes type 1 or 2, multiple sclerosis, rheumatoid arthritis, and a disease of the thyroid gland. ### Claim 4 (depends on 1) The method according to claim 1, wherein the method is configured to reduce a likelihood of, protect against or treat one or more selected from the group consisting of hay fever, food allergy, asthma, urticaria, neurodermitis, and atopic dermatitis. ### Claim 5 (depends on 1) The method according to claim 1, wherein the method is configured to reduce a likelihood of, protect against or treat one or more selected from the group consisting of hay fever and asthma. ### Claim 6 (depends on 2) The method according to claim 2, wherein the at least one grass is selected from the group of Meadow Foxtail (Alopecurus pratensis), timothy grass and timothy grass pollen (Phleum pratense L), Cock's Foot (Dactyhs glomerata), Yorkshire Fog (Holcus lannatus), English Raygrass (Lolium perenne), Smooth Meadow grass (Poa pratense), Rye (Secale cereale) or grasses from related species or a mixture thereof. ### Claim 7 (depends on 1) The method according to claim 1, wherein the composition comprises an arabinogalactan selected from the group consisting of compounds of the structure shown in FIG. 1. ### Claim 8 (depends on 1) The method according to claim 1, wherein the composition comprises at least one further active ingredient selected from the group of naturally occurring, isolated bacteria of the genus Lactococcus or fragments of said bacteria. ### Claim 9 (depends on 9) The method according to claim 9, wherein the bacteria are selected from Lactococcus lactis. ### Claim 10 (depends on 1) The method according to claim 1, wherein the composition comprises at least one further active ingredient comprising humic acid. ### Claim 11 (depends on 1) The method according to claim 1, wherein the composition is a pharmaceutical composition in form of an aerosol, aqueous solution, suspension, lyophilisate, or powder for nasal or inhalative application. ### Claim 12 (depends on 1) The method according to claim 1, wherein the composition is in form for nasal or inhalative administration. ### Claim 13 (depends on 1) The method according to claim 1, wherein the method is suitable for application for an infant (baby) or a pregnant, which due to a positive family anamnesis has an increased risk to develop any allergic disease or chronic inflammatory disease or which shows a first sign of such a disease. ### Claim 14 (depends on 1) The method according to claim 1, wherein the method is configured to provide a prophylactic antiallergenic effect such that said composition is administered before any onset of an allergic disease or an chronic inflammatory disease. ### Claim 15 (depends on 1) The method according to claim 1, wherein the method is suitable for application to a pregnant woman such that said reduction, protection or treatment of an infant will be obtained by the application of the composition to the pregnant mother. ### Claim 16 (depends on 1) The method according to claim 1, wherein the method is suitable for application to an infant. ### Claim 17 (depends on 1) The method according to claim 1, wherein the composition is administered to a child directly after birth thereof. ### Claim 18 (depends on 1) The method according to claim 1, wherein the method is suitable for application to a child during the first years of the child's life. ### Claim 19 (depends on 1) The method according to claim 1, wherein the method is suitable for application to a child during the first years of the child's life up to 8-10 years. ### Claim 20 (depends on 1) The method according to claim 1, wherein the method is suitable for application to a child within the first five years of the child's life. ### Claim 21 (depends on 1) The method according to claim 1, wherein the method is suitable for application to a child within the first two years of the child's life.